ScreenerHero

BCLIBrainstorm Cell Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · brainstorm-cell.com
1.030USD-15.57%Mkt Cap: 11.37M $P/E: —

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn propriet…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap11.37M $
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.31M $
Revenue/Share—
Last Price1.030 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS10501E2019
Valuation
P/E (Trailing)—
P/E (Forward)-1.04
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-1.17
EPS (TTM)-0.88
EPS (Forward)-1.02
52W Range
0.460046% of range1.690
52W High1.690 USD
52W Low0.4600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.22%
ROA-1008.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.97M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.02
Current Ratio—
Quick Ratio—
Book Value/Sh-0.9050 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 1, 2024
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.03M
Float—
Insiders11.18%
Institutions0.00%
Short Interest
Short Ratio1.3d
Short % Float6.46%
Short % Out.5.97%
Shares Short604.46K
Short (prev mo.)536.94K
Technical
SMA 500.9604 (+7.2%)
SMA 2000.7527 (+36.8%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)12.24K
Avg Vol (10d)55.01K
Technical Indicators
RSI (14)55.4
MACD0.0329
MACD Signal-0.0007
MACD Hist.+0.0336
BB Upper1.146 USD
BB Middle0.9069 USD
BB Lower0.6673 USD
BB Width52.82%
ATR (14)0.1301 USD
Vol Ratio (20d)2.37x